Since the beginning of August last year, the Chinese pharmaceutical company Sinovac Biotech announced its strategy to begin to settle in our country with the first production plant for vaccines against COVID-19 and other diseases such as influenza and hepatitis, becoming one of the company’s main investments in Latin America.
As reported this weekend by the Financial Journal, the pharmaceutical mega project It will be installed in Quilicura and the company plans to start operations at the end of 2022. In fact, there are already dozens of people hired to carry out the preparations for the development of the business, and a delegation of Sinovac executives is expected to arrive in early March to assess the progress of the construction.
Within the convictions of the firm, there is the goal of producing 50 million vaccines against the initially announced diseases and possibly, to counteract polio and chickenpox. Likewise, the technology necessary for its development is only waiting to be imported from the Asian giant to our country.
“There are different profiles that we are looking for: laboratory technicians, engineers, biochemists and pharmacists,” said the Vice President of Corporate Affairs of the company’s local headquarters, Virginia Garretón. This considering that it is an initial investment of US$100 million, necessary for the construction, operation and maintenance of the plant.
Read also: Sinovac will install a plant in Chile and plans to start operating in March 2022: It would be a center for all of Latin America
Another key point is that this vaccine factory is currently the pharmaceutical company’s short-term goal. In this sense, the Sinovac Biotech Chile executive adds that the company is considering a “research and development” plan, since it is not just about producing vaccines. Governments must be convinced that inoculations are safe“.
Likewise, the creation of master’s and postgraduate programs is planned with the intention of expanding the number of professionals with the necessary training to produce, monitor and market vaccines.
–
